GP
TMO icon

Geneva Partners’s Thermo Fisher Scientific TMO Stock Holding History

Geneva Partners’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,218
Closed -$617K – 81
2023
Q3 		$617K Sell
1,218
-1,574
-56% -$839K 0.41% 45
2023
Q2 		$1.46M Sell
2,792
-100
-3% -$54K 0.95% 33
2023
Q1 		$1.67M Sell
2,892
-20
-0.7% -$11.3K 1.43% 30
2022
Q4 		$1.6M Sell
2,912
-1,123
-28% -$595K 1.51% 24
2022
Q3 		$2.05M Buy
4,035
+24
+0.6% +$13.4K 2.34% 17
2022
Q2 		$2.18M Sell
4,011
-222
-5% -$122K 2.14% 19
2022
Q1 		$2.5M Sell
4,233
-1,008
-19% -$579K 1.55% 25
2021
Q4 		$3.5M Buy
5,241
+28
+0.5% +$17.5K 1.66% 22
2021
Q3 		$2.98M Buy
5,213
+460
+10% +$252K 1.41% 29
2021
Q2 		$2.4M Sell
4,753
-15
-0.3% -$7.08K 1.1% 31
2021
Q1 		$2.18M Sell
4,768
-72
-1% -$34.4K 1.13% 31
2020
Q4 		$2.25M Sell
4,840
-1,670
-26% -$783K 1.19% 31
2020
Q3 		$2.87M Sell
6,510
-130
-2% -$53.7K 1.76% 24
2020
Q2 		$2.41M Sell
6,640
-25
-0.4% -$8.38K 1.69% 26
2020
Q1 		$1.89M Sell
6,665
-460
-6% -$145K 2.69% 17
2019
Q4 		$2.31M Sell
7,125
-85
-1% -$25.8K 1.6% 26
2019
Q3 		$2.1M Buy
7,210
+125
+2% +$35.8K 1.63% 26
2019
Q2 		$2.08M Sell
7,085
-3,225
-31% -$888K 1.68% 24
2019
Q1 		$2.73M Buy
10,310
+1,165
+13% +$290K 2.32% 16
2018
Q4 		$2.05M Buy
9,145
+3,400
+59% +$798K 2.37% 16
2018
Q3 		$1.4M Buy
+5,745
New +$1.32M 1.08% 35

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Geneva Partners's TMO Position: Q4 2023 in Review

Geneva Partners sold out of Thermo Fisher Scientific (TMO) in Q4 2023, closing a stake of 1,218 shares — an estimated $617K sold.

Geneva Partners first reported a position in TMO in Q3 2018 and held it in 21 quarters. The position peaked at $3.5M in Q4 2021. 2,488 funds tracked by Wall St. Rank hold TMO as of Q4 2023.

  • Geneva Partners reported no remaining Thermo Fisher Scientific position as of Q4 2023 after selling out during the quarter.
  • Geneva Partners sold 1,218 Thermo Fisher Scientific shares in Q4 2023, an estimated $617K.
  • Geneva Partners first reported a position in Thermo Fisher Scientific in Q3 2018 and held it in 21 quarters.
  • Geneva Partners's Thermo Fisher Scientific position peaked at $3.5M in Q4 2021.
  • 2,488 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2023.

Based on Geneva Partners's 13F filing for Q4 2023, filed 31 Jan 2024.